Skip to content

Study · Systematic review · n = 3,962 · 2024

14 results

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.

Qin W, Yang J, Deng C, Ruan Q, Duan K

Diabetes, obesity & metabolism28 Nov 2023Cited by 57 (Europe PMC)

PMID38016699 (opens in a new tab)DOI10.1111/dom.15386 (opens in a new tab)PepBankPUB-38016699
Read at sourcePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg reduced the percentage of body weight more than placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in body weight
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Mean difference, body weight
    −11.8%
    semaglutide vs placebo

    Source sentences

    Summary
    in comparison to the placebo group, semaglutide caused a significant and sustainable reduction in the percentage of body weight (BW; mean difference [MD]: -11.80% [95% confidence interval {CI} -12.93, -10.68]; P < 0.00001
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  2. 02HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg reduced absolute body weight more than placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide led to more kilograms of weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute body weight change
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Mean difference, absolute body weight
    −12.2 kg
    semaglutide vs placebo

    Source sentences

    Summary
    a decrease in absolute BW (MD: -12.2 kg [95% CI -13.3, -11.1]; P < 0.00001
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  3. 03HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg reduced body mass index more than placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide lowered body mass index more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index change
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Mean difference, body mass index
    −4.5 kg/m2
    semaglutide vs placebo

    Source sentences

    Summary
    body mass index (MD: -4.5 kg/m2 [95% CI -4.9, -4.1]; P < 0.00001
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  4. 04HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg reduced waist circumference more than placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide shrank waist size more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference change
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Mean difference, waist circumference
    −9.4 cm
    semaglutide vs placebo

    Source sentences

    Summary
    waist circumference (MD:-9.4 cm [95% CI -10.1, -8.8]; P < 0.00001
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  5. 05HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, a higher proportion of patients on semaglutide than on placebo lost more than 5% of body weight.

    In plain wordsIn overweight or obese adults without diabetes, more people on semaglutide than on placebo lost more than 5% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss exceeding 5%
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  6. 06HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, a higher proportion of patients on semaglutide than on placebo lost more than 10% of body weight.

    In plain wordsIn overweight or obese adults without diabetes, more people on semaglutide than on placebo lost more than 10% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss exceeding 10%
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  7. 07HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, a higher proportion of patients on semaglutide than on placebo lost more than 15% of body weight.

    In plain wordsIn overweight or obese adults without diabetes, more people on semaglutide than on placebo lost more than 15% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss exceeding 15%
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  8. 08HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, a higher proportion of patients on semaglutide than on placebo lost more than 20% of body weight.

    In plain wordsIn overweight or obese adults without diabetes, more people on semaglutide than on placebo lost more than 20% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss exceeding 20%
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Moreover, it achieved a higher proportion of patients who experienced weight loss exceeding 5%, 10%, 15% and 20%.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  9. 09HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg showed significant efficacy in controlling blood pressure compared with placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide was better than placebo at controlling blood pressure.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedBlood pressure control
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  10. 10HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg showed significant efficacy in controlling blood sugar levels compared with placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide was better than placebo at controlling blood sugar.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedBlood sugar control
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  11. 11HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg showed significant efficacy in controlling C-reactive protein levels compared with placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide was better than placebo at controlling a blood marker of inflammation.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedC-reactive protein level
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  12. 12HumanSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, semaglutide 2.4 mg showed significant efficacy in controlling lipid profiles compared with placebo.

    In plain wordsIn overweight or obese adults without diabetes, semaglutide was better than placebo at controlling blood fats.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedLipid profile
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, semaglutide showed significant efficacy in controlling blood pressure, blood sugar levels, C-reactive protein levels, and lipid profiles.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  13. 13HumanSystematic reviewSafety outcome

    In overweight or obese adults without diabetes, gastrointestinal adverse reactions were the most common adverse effects of semaglutide 2.4 mg and were more frequent than with placebo.

    In plain wordsIn overweight or obese adults without diabetes, stomach and gut side effects were the most common with semaglutide and were more frequent than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse reactions
    Study

    n = 3,962

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Measurements

    Risk ratio
    1.49 ratio
    semaglutide vs placebo

    Source sentences

    Summary
    In terms of safety, the most common adverse effects following semaglutide treatment were gastrointestinal adverse reactions (risk ratio: 1.49 [95% CI 1.38, 1.60]; P < 0.00001)
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.
  14. 14HumanSystematic reviewSafety outcome

    In overweight or obese adults without diabetes, gastrointestinal adverse reactions to semaglutide 2.4 mg were generally mild to moderate and temporary.

    In plain wordsIn overweight or obese adults without diabetes, stomach and gut side effects of semaglutide were mostly mild to moderate and short.

    Peptide
    Semaglutide
    Outcome
    Not applicableSeverity of gastrointestinal adverse reactions
    Study

    n = 3,962

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg once weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    which were generally mild to moderate in severity and temporary.
    2 context sentences
    Summary · context
    Our aim was to identify randomized controlled trials (RCTs) that compared the efficacy of semaglutide administered once weekly with placebo in overweight or obese adults.
    Summary · context
    Six RCTs comprising 3962 overweight or obese individuals were identified.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.